dipyridamole has been researched along with Adult Spinal Muscular Atrophy in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oprişoreanu, AM | 1 |
| Smith, HL | 1 |
| Krix, S | 1 |
| Chaytow, H | 1 |
| Carragher, NO | 1 |
| Gillingwater, TH | 1 |
| Becker, CG | 1 |
| Becker, T | 1 |
1 other study available for dipyridamole and Adult Spinal Muscular Atrophy
| Article | Year |
|---|---|
Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy.
Topics: Animals; Automation; Axons; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Gene | 2021 |